The Epibase^® technology has the capability to identify both Class-I and
Class-II restricted T-cell epitopes present in therapeutic proteins or
antibodies.

Epibase^® is widely used to generate Immunoprofiles of the T-cell epitopes in therapeutic proteins.

The platform assists you in the different stages of drug development:

• Relative comparison of immunogenicity of drug leads:
  compare the epitope content of several protein variants entering the drug development cycle and compare their T-cell epitope content.
• Early stage rejection of drug leads with “nasty bits”:
  putative T-cell epitopes can be discovered at research level, allowing to select the optimal protein leads or to remove epitopes while optimizing the proteins.
• Focus on HLA subtypes that are disease specific:
  In certain cases, HLA alleles are linked with diseases. Epibase^® allows to explore if the drug candidates are safe for the targeted patient population.
• Immunogenicity documentation in regulatory filings:
  What is the expected T-cell driven immunogenicity of the drug lead?

Immunotuning^®

Immunotuning^® is AlgoNomics' combined know-how in T-cell epitope removal
(Deimmunization), B-cell epitope removal (Humanization) and T-cell epitope
alteration.

Proteins can induce an antibody response (B-cell driven), when both T-helper
epitopes and B-cell epitopes are present. AlgoNomics' Tripole^® platform is
optimally suited to alter B-cell epitopes to reduce potential antibody
recognition sites. This application has been recurrently used to humanize
murine therapeutic antibodies. Optimally, this is done in conjunction with
an Epibase^® HLA-ClassII profile, to reduce also the T-helper response.

Proteins can induce T-cell responses, even if they are fully human versions.
Many types of antibodies, also when humanized or fully human, can induce
this response. In such a situation the T-cells recognize particular sites of
these proteins or antibodies as non-self, and thereby generate immune
reactions or immunogenic side-effects. AlgoNomics offers the technology to
re-engineer these protein or antibody regions without compromising the
efficacy. By substituting the relevant amino acids of the immunogenic
regions the immunization can be removed.

For specialized applications, T-cell epitopes need to be altered or
enhanced. Here also, the combination of Epibase^® and Tripole^® technology
lead to a fast identification of alterations to be made to a peptide or
therapeutic protein.